De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NeoImmuneTech Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Luke Yun Oh

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	2.2yrs

Recente managementupdates

Recent updates

Companies Like NeoImmuneTech (KOSDAQ:950220) Could Be Quite Risky

Aug 13

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

Mar 22

CEO

Luke Yun Oh

less than a year

Tenure

Dr. Luke Yun Suk Oh Ph. D. is President of NeoImmuneTech, Inc. from January 15, 2024 and serves as its Chief Executive Officer since March 29, 2024 and serves as its Chairman since 2024. Dr. Oh is an exper...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Luke Yun Oh	President	less than a year	geen gegevens	geen gegevens
Tae Woo Kim	Chief Financial Officer	no data	geen gegevens	0% ₩ 0
Goongjin Namgoong	Chief Operating Officer	4.8yrs	geen gegevens	0% ₩ 0
Byung Lee	Chief Scientific Officer	3.6yrs	geen gegevens	0% ₩ 0

3.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van A950220 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Luke Yun Oh	President	less than a year	geen gegevens	geen gegevens
Rafi Ahmed	Member of Scientific Advisory Board	4.9yrs	geen gegevens	geen gegevens
Soo-Hyoung Kang	Director	no data	geen gegevens	geen gegevens
Jin-Hyoung Kang	Director	3.4yrs	geen gegevens	geen gegevens
Sung-June Hong	Director	less than a year	geen gegevens	geen gegevens
Richard Kim	Member of Scientific Advisory Board	2.2yrs	geen gegevens	geen gegevens
Keith Watson	Member of Scientific Advisory Board	2.2yrs	geen gegevens	geen gegevens
Hyunseok Kang	Member of Scientific Advisory Board	2.2yrs	geen gegevens	geen gegevens
Young Chae	Member of Scientific Advisory Board	2.2yrs	geen gegevens	geen gegevens
Benny Chen	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens
Su-Hyung Park	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens
Choonggoo Kang	Director	less than a year	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van A950220 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.2 jaar), wat duidt op een nieuw bestuur.

NeoImmuneTech Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Appoints Luke Oh as President

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

Recent updates

New minor risk - Share price stability

Companies Like NeoImmuneTech (KOSDAQ:950220) Could Be Quite Risky

NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

New minor risk - Share price stability

NeoImmuneTech, Inc. Appoints Luke Oh as President

Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome

New minor risk - Share price stability

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors

No independent directors

Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022

NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7

NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global (Beijing) Technology, Inc.

NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

Neoimmunetech to Present At Society for Neuro-Oncology

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

NeoImmuneTech, Inc. Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

NeoImmuneTech, Inc. Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur